Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria

Journal of Molecular Microbiology and Biotechnology

Volumn 3, Issue 2, 2001, Pages 225-236

  Lomovskaya, Olga ^a   Watkins, Will ^a  

^a Microcide Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 CPTC; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARRIER PROTEIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; GLYCYLCYCLINE DERIVATIVE; INF 240; INF 271; INF 277; INF 392; INF 55; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MC 02595; MC 510051; PHENYLALANYLARGININE 2 NAPHTHYLAMIDE; PROTEIN INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; RO 07 3149; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; UK 57562; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DRUG DETERMINATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TRANSPORT; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; PROTEIN INTERACTION; PSEUDOMONAS AERUGINOSA; TRANSPOSON;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PROTEINS; CARRIER PROTEINS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MEMBRANE PROTEINS;

ESCHERICHIA COLI; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0035079739     PISSN: 14641801     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (133)

1. The role of the outer membrane of Pseudomonas aeruginosa in the uptake of aminoglycoside antibiotics
2. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides
3. A new chloramphenical and florfenicol resistance gene flanked by two integron structures in Salmonella typhimurium DT104
4. Emergence of mefA and mefE genes in beta-haemolytic streptococci and pneumococci in France
5. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic finrosis
6. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine
7. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647. Tested against Haemophilus influenzae and Moraxella catarrhalis strains
8. Efflux pump inhibitors enhance the activity of antimicrobial agents against a broad selection of bacteria
9. Detection of multidrug-resistant Salmonella enterica serotype typhimurium DT104 based on a gene which confers cross-resistance to florfenicol and chloramphenicol
10. Mechanisms of beta-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey
11. CP-544372: MIC90 studies and killing kinetics against key espiratory tract pathogens
12. Efflux-mediated resistance in mutants of Streptococcus pneumonia selected with newer fluoroquinolones
13. The chemistry and biological profile of trovafloxacin
14. Newer penicillins and beta-lactamase inhibitors
15. Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993
16. Prevalence of efflux mechanisms among clinical isolates of fluoroquinolone resistant Pseudomonas aeroginosa
17. Tetracyclines, molecular and clinical aspects
18. Molecular cloning and functional analysis of a novel macrolide resistance determinant mefA from Streptomyces pyogenes
19. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation
20. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use
21. Antipneumococcla activity of ABT-773 compared to those of 10 other agents
22. A single membrane-embedded negative charge is critical for recognizing positively charged drugs by the Escherichia coli multidrug resistance protein MdfA
23. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals
24. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus
25. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO
26. nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeroginosa
27. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
28. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains
29. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects
30. Activities of trovafloxacin compared with those of other fluoroquinolones againsts purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus
31. Potentiation of levofloxacin by a broad-spectrum efflux pump inhibitor in mouse models of infectin caused by Pseudomonas aeruginosa
32. Potentiation of levoflocaxin by MC-02, 595, a broad-spectrum efflux pump inhibitor in mouse models of infection due to Pseudomonas aeuruginosa with combinations of different Mex pumps expression and target mutations
33. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci
34. Involvoment of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa
35. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa
36. Screening of an inhibitor of the tetracycline efflux pump in a tetracycline-resistant clinical-isolate of Staphylococcus aureus 743
37. Bacteria lacking a multidrug pump: A sensitive tool for drug discovery
38. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa
39. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa
40. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004
41. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus
42. In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeroginosa
43. Detection of florfenicol resistance genes in Escherichia coli isolated from sick chickens
44. Sequence analysis of the florfenicol resistance gene encoded in the transferable R-plasmid of a fish pathogen, Pasteurella piscicida
45. New macrolides: Expanded horizons for an old class of antibiotics
46. Carbapenen activities against Pseudomonas aeriginosa: Respective contributions of OprD and efflux systems
47. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa
48. Differential selection of multidrug efflux systems by quinolones in Pseudomanas aeruginosa
49. Efflux pumps in bacteria: Overview, clinical relevance, and potential pharmaceutical target
50. Inteerplay between efflux pumps may provide either additive or multiplicative effects on drug resistance
51. MF-EA-371a and MF-EA-371b, novel bacterial efflux pump inhibitors from microbial phermentations
52. Peptidomimetics of dipeptide amide efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa
53. Active efflux mechanisms for antimicrobial resistance
54. Multidrug resistance pumps in bacteria: Variations on a theme
55. Role of efflux pumps(s) in intrinsic resistance of Pseudomonas aeruginosa: Active efflux as a contributing factor to beta-lactam resistance
56. Use of genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa
57. Targeting efflux pumps in Pseudomonas aeruginosa
58. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy
59. A variety of gram-positive bacteria carry mobile mef genes
60. Active efflux of antimicrobial agents in wild-type strains of enterococci
61. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa
62. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine
63. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus
64. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus
65. Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa
66. Contribution of the MexXY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa
67. Effect on salt concentrtion on the apparent in vitro susceptibility of Pseudomonas and other gram-negative bacilli to gentamicin
68. The most frequent aminoglycoside resistance mechanisms - Changes with time and geographic area: A reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups
69. Bioenergetics of the staphylococcal multidrug export protein QacA. Identification of distinct binding sites for monovalent and divalent cations
70. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei
71. Expression of genes associated with antibiotic extrusion in Pseudomonas aeruginosa
72. Resistance to beta-lactam antibiotics in Pseudomonas aeruginosa due to interplay betwen the MexAB-OprM efflux pump and beta-lactamase
73. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein
74. Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines
75. Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria
76. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter
77. Quinolone resistance mediated by norA: Physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome
78. Prevention of drug access to bacterial targets: Permeability barriers and active efflux
79. Antibiotic resistance caused by gram-negative multidrug efflux pumps
80. Multiple antibiotic resistance and efflux
81. The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access?
82. Molecular basis of bacterial outer membrane permeability
83. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics
84. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump
85. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
86. Microbial genome analyses: Global comparisons of transport capabilities based on phylogenies, bioenergetics and substrate specificities
87. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
88. Mechanism of fluoroquinolone resistance: An update 1994-1998
89. Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae
90. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
91. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria
92. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa
93. Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: Regulation by iron and possible involvement in the secretion of the siderophore pyoverdine
94. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression
95. Molecular characterization of multidrug resistance in Streptococcus mitis
96. The secondary multidrug transporter LmrP contains multiple drug interaction sites
97. Addressing the stability of c-capped dipeptide efflux pump inhibitors that potentiate the activity of lovofloxacin in Pseudomonas asruginosa
98. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin
99. Nomenclature for macrolide and macrolide-lincosamide-streptogramine B resistance determinants
100. Epidemiology of tetracycline-resistance determinants
101. AcrD of Eschericia coli is an aminoglycoside efflux pump
102. The major facilitator superfamily
103. Molecular phylogeny as a basis for the classification of transport proteins from bacteria, archaea and eukarya
104. Phylogenetic characterization of novel transport protein families revealed by genome analyses
105. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria
106. Molecular basis of antimicrobial resistance in non-typable Haemophilus influenzae
107. Tetracyclines: Antibioic action, uptake, and resistance mechanisms
108. Origin of tetracycline efflux proteins: Conclusions from nucleotide sequence analysis
109. Identification of a teracycline efflux resistance reverser UK-57,562
110. A novel glycylcycline, 9-(N,N-dimethylglycyclamido)-6-demethyl-6- deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metaltetracycline/H+ antiporter
111. Role of OprM in the intrinsic drug resistance and pathogenicity of Pseudomonas aeruginosa
112. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
113. Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5′-methoxyhynocarpine, a multidrug pump inhibitor
114. Recent developments in tetracycline antibiotics
115. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
116. Active efflux of bile salts by Escherichia coli
117. Efflux pump inhibitors
118. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa
119. The RND permease surefamily: An ancient, ubiquitous and diverse family that includes human disease and development proteins
120. Antibiotic efflux pumps
121. An inhibitor of Mex pumps from Pseudomonas aeruginosa is also a substrate of these pumps
122. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability
123. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabit endocarditis model
124. Quinolone susceptibility of norA-disrupted Staphylococcus aureus
125. EmrE, an Escherichia coli 12-kDa multidrug transporter, exchanges toxic cations and H+ and is soluble in organic solvents
126. The role of mex-gene products in antibiotic extrusion in Pseudomonas aeruginosa
127. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
128. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones
129. Multidrug resistance mechanisms: Drug efflux across two membranes
130. AcrA is a highly asymmetric protein capable of spanning the periplasm
131. Bypassing the periplasm: Reconstitution of the AcrAB multidrug efflux pump of Escherichia coli
132. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM
133. Activity of aminoglycoside antibiotics against Pseudomonas aeruginosa: Specificity and site and calcium and magnesium antagonism